Zacks Research Predicts Biogen’s Q4 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Zacks Research increased their Q4 2025 EPS estimates for shares of Biogen in a research note issued on Thursday, January 15th. Zacks Research analyst Team now expects that the biotechnology company will earn $1.49 per share for the quarter, up from their prior estimate of $1.48. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, topping the consensus estimate of $3.89 by $0.92. The business had revenue of $2.53 billion for the quarter, compared to analysts’ expectations of $2.34 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS.

A number of other analysts also recently issued reports on the company. Citigroup raised their target price on Biogen from $153.00 to $180.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. Sanford C. Bernstein upped their price objective on shares of Biogen from $157.00 to $197.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Wedbush lifted their target price on shares of Biogen from $135.00 to $143.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. UBS Group assumed coverage on shares of Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 target price on the stock. Finally, Jefferies Financial Group increased their price target on shares of Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, November 28th. Ten research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $190.50.

Biogen Stock Performance

Shares of Biogen stock opened at $164.42 on Monday. The business’s 50 day moving average price is $175.04 and its 200 day moving average price is $152.14. The company has a market cap of $24.12 billion, a price-to-earnings ratio of 14.99, a PEG ratio of 1.37 and a beta of 0.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. Biogen has a one year low of $110.04 and a one year high of $190.20.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently made changes to their positions in the stock. Elevation Point Wealth Partners LLC purchased a new position in shares of Biogen during the 2nd quarter worth approximately $25,000. Rothschild Investment LLC boosted its position in shares of Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after buying an additional 88 shares during the period. Accredited Wealth Management LLC grew its stake in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares in the last quarter. Concord Wealth Partners raised its holdings in shares of Biogen by 100.0% in the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 114 shares during the period. Finally, NewSquare Capital LLC raised its holdings in shares of Biogen by 134.6% in the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.